REG-Arix Bioscience PLC Harpoon announces closing of public offering

Arix BioscienceAnnouncement

12/01/2021 07:00

============

   Arix Bioscience PLC (ARIX)
   Harpoon announces closing of public offering

   12-Jan-2021 / 07:00 GMT/BST
   Dissemination of a Regulatory Announcement, transmitted by EQS Group.
   The issuer is solely responsible for the content of this announcement.

   ══════════════════════════════════════════════════════════════════════════

                              Arix Bioscience plc

                  Harpoon announces closing of public offering

   LONDON, 12 January 2021: Arix Bioscience plc ("Arix", LSE: ARIX), a global
   venture capital company focused on investing in and building  breakthrough
   biotech companies, notes that its portfolio company, Harpoon Therapeutics,
   Inc.  ("Harpoon",  Nasdaq:  HARP),  has  announced  the  closing  of   its
   underwritten public  offering of  6,764,704 shares  of its  common  stock,
   which includes 882,352 shares sold upon the underwriters' full exercise of
   their option to purchase additional  shares, resulting in aggregate  gross
   proceeds of approximately  $115.0 million,  before deducting  underwriting
   discounts  and  commissions  and  offering  expenses  payable  by  Harpoon
   Therapeutics.

   Following the offering, Arix retains a stake of 6.9% in Harpoon, amounting
   to 2,208,667 shares of common stock.

   The   announcement    can   be    accessed   on    Harpoon's website    at
    1 https://ir.harpoontx.com/news-releases    and full    text    of    the
   announcement from Harpoon is contained below.

    

                                      ENDS 

   Enquiries

   For more information on Arix, please contact:

    

   Arix Bioscience plc

   Charlotte Parry, Head of Investor Relations

   +44 (0)20 7290 1072

    2 charlotte@arixbioscience.com

    

   Optimum Strategic Communications

   Supriya Mathur, Shabnam Bashir, Manel Mateus

   +44 (0)20 3922 1906

    3 optimum.arix@optimumcomms.com

    

   About Arix Bioscience plc

   Arix Bioscience  plc  is  a  global venture  capital  company  focused  on
   investing  in   and  building   breakthrough  biotech   companies   around
   cutting-edge advances in life sciences.

   We collaborate  with exceptional  entrepreneurs and  provide the  capital,
   expertise  and  global  networks  to  help  accelerate  their  ideas  into
   important new treatments for patients. As a listed company, we are able to
   bring this exciting  growth phase of  our industry to  a broader range  of
   investors.

   For more information please visit:  4 www.arixbioscience.com

    

   Harpoon Therapeutics Announces Closing of Public Offering of Common Stock

    

        Underwriters Fully Exercise Option to Purchase Additional Shares

   SOUTH SAN FRANCISCO, Calif., Jan. 11, 2021 -- Harpoon Therapeutics, Inc.
   (Nasdaq: HARP) announced today the closing of its underwritten public
   offering of 6,764,704 shares of its common stock, which includes 882,352
   shares sold upon the underwriters' full exercise of their option to
   purchase additional shares, resulting in aggregate gross proceeds of
   approximately $115.0 million, before deducting underwriting discounts and
   commissions and offering expenses payable by Harpoon Therapeutics.

   SVB Leerink and Piper Sandler acted as joint bookrunning managers for the
   offering. Baird and Truist Securities acted as co-lead managers for the
   offering. Roth Capital Partners acted as co-manager for the offering.

   The shares of common stock were offered pursuant to a "shelf" registration
   statement previously filed with and declared effective by the Securities
   and Exchange Commission (SEC). The offering is being made only by means of
   a prospectus supplement and accompanying prospectus, copies of which may
   be obtained from: SVB Leerink LLC, Attention: Syndicate Department, One
   Federal Street, 37th Floor, Boston, MA 02110, by telephone at (800)
   808-7525, ext. 6132 or by email at syndicate@svbleerink.com or Piper
   Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall,
   J12S03, Minneapolis, MN 55402, by telephone at (800) 747-3924 or by email
   at  5 prospectus@psc.com.

   This press release shall not constitute an offer to sell, or a
   solicitation of an offer to buy, nor shall there be any sale of these
   securities in any state or jurisdiction in which such offer, solicitation
   or sale would be unlawful prior to registration or qualification under the
   securities laws of any such state or jurisdiction. Any offer, if at all,
   will be made only by means of a prospectus supplement and accompanying
   prospectus, which are a part of the effective registration statement.

   Contacts: 
   Harpoon Therapeutics, Inc.
   Georgia Erbez
   Chief Financial Officer
   650-443-7400
   media@harpoontx.com

   Westwicke ICR
   Robert H. Uhl
   Managing Director
   858-356-5932 
   robert.uhl@westwicke.com

    

    

   ══════════════════════════════════════════════════════════════════════════

   ISIN:           GB00BD045071
   Category Code:  MSCU
   TIDM:           ARIX
   LEI Code:       213800OVT3AHQCXNIX43
   OAM Categories: 3.1. Additional regulated information required to be
                   disclosed under the laws of a Member State
   Sequence No.:   91241
   EQS News ID:    1159934


    
   End of Announcement EQS News Service

   ══════════════════════════════════════════════════════════════════════════

    6 fncls.ssp?fn=show_t_gif&application_id=1159934&application_name=news&site_id=reuters8

References

   Visible links
   1. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=6b747ef884586fd08f9b1bf9f3b4700a&application_id=1159934&site_id=reuters8&application_name=news
   2. mailto:charlotte@arixbioscience.com
   3. mailto:optimum.arix@optimumcomms.com
   4. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=889c637ce21c3a47a35c39202ebd9825&application_id=1159934&site_id=reuters8&application_name=news
   5. mailto:prospectus@psc.com


============